News By Tag Industry News News By Location Country(s) Industry News
| Antipsychotics Market to 2017 - Patent Expiries for Zyprexa, Abilify, Seroquel and GeodonGlobal Antipsychotics Market Is Expected To Decline Due To Patent Expiries of Major Drugs
By: Rajesh Gunnam The global antipsychotics market has shown a rising trend from 2002, growing at a Compound Annual Growth Rate (CAGR) of 4.8% to reach $14 billion in 2010. Newer agents (atypical antipsychotics) However, the patent expiries of the leading antipsychotics such as Zyprexa, Abilify, Geodon, and Seroquel in the forecast period, followed by the immediate entry of generic versions are expected to increase price competition in the global antipsychotics market and so may limit the commercial opportunities to pipeline molecules. As a result the global antipsychotics market is expected to decline at a CAGR of 0.4% from $14 billion in 2010 to $13.8 billion in 2017. The schizophrenia therapeutics market is highly competitive with many typical and atypical antipsychotics contributing to the market. The atypical antipsychotics are the more preferred drugs for the treatment of schizophrenia due to their better safety and efficacy profile. For Sample Pages, please click or add the below link to your browser: http://www.gbiresearch.com/ The global schizophrenia therapeutics market generated revenues of about $9.9 billion in 2010 growing at a CAGR of 4.5% from $7 billion in 2002. This market is expected to witness price competition in the forecast period due to the series of patent expiries of major drugs such as Zyprexa (2011), Geodon (2012), Abilify (2015) and Saphris (2015). The launch of Latuda (lurasidone) GBI Research, the leading business intelligence provider, has released its latest research “Antipsychotics Market to 2017 - Patent Expiries for Zyprexa, Abilify, Seroquel and Geodon and the Launch of Generic Versions Will Limit Commercial Opportunities for Pipeline Molecules”, which provides insights into the global antipsychotics market until 2017. The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research’s team of industry experts. The report provides an in-depth analysis of the antipsychotics market for bipolar disorder and schizophrenia. The report also provides the share of generics in the global antipsychotics market as well as in each indication market. The report examines the global bipolar disorder and schizophrenia treatment usage patterns. In addition, geographical distribution of the antipsychotic market across the US, the top five countries of Europe and in Japan is provided. The report also includes insights into the antipsychotics R&D product pipeline and explores the competitive landscape including major players in the antipsychotics market. Finally, the report also includes an analysis on the Mergers and Acquisitions (M&A) and licensing agreements that have recently taken place in the antipsychotics market. For further details, please click or add the below link to your browser: http://www.gbiresearch.com/ Visit our report store: http://www.gbiresearch.com For more details contact: pressreleases@ North America: +1 646 395 5477 Europe: Asia Pacific: # # # GBI Research is a market-leading provider of business intelligence reports. GBI Research covers worldwide markets and issues, supplies actionable data and forecasts and is driven by industry leaders’ insights. GBI Research provides a broad spectrum of reports across the healthcare and energy industries and its online offering is easy to navigate - a comprehensive resource for business information needs End
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Account Phone Number